WN
ANIK icon

Williams & Novak’s Anika Therapeutics ANIK Stock Holding History

Williams & Novak’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,193
Closed -$136K – 146
2025
Q4 		$136K Buy
14,193
+3,353
+31% +$32.1K 0.1% 113
2025
Q3 		$102K Buy
+10,840
New +$104K 0.08% 125

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $585M AUM 5.18% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Williams & Novak's ANIK Position: Q1 2026 in Review

Williams & Novak sold out of Anika Therapeutics (ANIK) in Q1 2026, closing a stake of 14,193 shares — an estimated $136K sold.

Williams & Novak first reported a position in ANIK in Q3 2025 and held it in 2 quarters. The position peaked at $136K in Q4 2025. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Williams & Novak reported no remaining Anika Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Williams & Novak sold 14,193 Anika Therapeutics shares in Q1 2026, an estimated $136K.
  • Williams & Novak first reported a position in Anika Therapeutics in Q3 2025 and held it in 2 quarters.
  • Williams & Novak's Anika Therapeutics position peaked at $136K in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Williams & Novak's 13F filing for Q1 2026, filed 21 Apr 2026.